A review of the latest strategies for managing oestrogen therapy resistance in ER+/HER2− metastatic breast cancer, focusing on biomarker-driven approaches and novel treatments like elacestrant.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


